Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
NEW YORK, Jan. 11, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Endologix, Inc. (“Endologix” or the “Company”) (NASDAQ:ELGX) and certain of its officers. The class action, filed in United States District Court, Central District of California, and docketed under 17-cv-00061, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Endologix securities between August 2, 2016 and November 16, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Endologix securities during the Class Period, you have until March 6, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
Endologix develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally.
Endologix’s products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms. One of the Company’s products is built on the platform of endovascular sealing (“EVAS”). Endologix’s current EVAS product is the Nellix® EndoVascular Aneurysm Sealing System (“Nellix EVAS System”).
The Nellix EVAS System is currently engaged in the U.S. Food and Drug Administration (“FDA”) premarket approval process (the “PMA process”), which requires Endologix to collect and submit nonclinical and human clinical data on Nellix EVAS System for its intended use to demonstrate that it is safe and effective. In the PMA process, the FDA will approve the medical device and thereby authorize its commercial distribution in the U.S. if it determines that the probable benefits outweigh the risks for the intended patient population, and, therefore, makes a determination of reasonable assurances of safety and effectiveness.
In December 2013, Endologix received Investigational Device Exemption (“IDE”) approval in the United States to begin a clinical trial for the Nellix EVAS System, which commenced in January 2014 (the “IDE Study”). Enrollment in the IDE study was completed in November 2014. In the third quarter of 2015, Endologix obtained IDE continued access approval for additional patients.
On May 26, 2016, Endologix reported purportedly positive clinical data from the IDE Study and submitted the results to the FDA as part of the PMA process for the Nellix EVAS System.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its NellixAr EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix's public statements were materially false and misleading at all relevant times.
On November 16, 2016, before market hours, Endologix issued a press release entitled “Endologix Provides Update on Nellix PMA Process,” revealing “that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix® EndoVascular Aneurysm Sealing System (Nellix EVAS System).”
On this news, Endologix’s share price fell $2.02, or over 20.5%, from its previous closing price, to close at $7.82 on November 16, 2016, damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]
